Q2 Earnings Estimate for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Alumis in a note issued to investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($1.48) per share for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis’ Q3 2025 earnings at ($1.38) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.46) EPS, FY2026 earnings at ($5.19) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($2.04) EPS.

A number of other analysts have also commented on ALMS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Alumis in a research report on Wednesday. Finally, Oppenheimer assumed coverage on Alumis in a report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $26.00.

Alumis Trading Down 4.5 %

NASDAQ ALMS opened at $4.70 on Wednesday. Alumis has a one year low of $3.18 and a one year high of $13.53. The stock has a 50-day moving average of $5.43 and a 200 day moving average of $8.38.

Hedge Funds Weigh In On Alumis

A number of hedge funds have recently modified their holdings of ALMS. Foresite Capital Management VI LLC purchased a new position in shares of Alumis during the 4th quarter valued at $33,033,000. Samsara BioCapital LLC bought a new position in shares of Alumis in the third quarter worth about $34,886,000. Geode Capital Management LLC purchased a new stake in shares of Alumis during the third quarter worth about $3,266,000. Norges Bank bought a new stake in Alumis during the 4th quarter valued at approximately $1,606,000. Finally, Foresite Capital Management V LLC lifted its holdings in Alumis by 3.5% in the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after purchasing an additional 194,459 shares in the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.